接受抗CD20单克隆抗体治疗血液恶性肿瘤成人中灭活水痘-带状疱疹病毒疫苗的安全性和免疫原性
这项开放标签、单臂、多中心I期研究(NCT01460719)纳入80例接受抗CD20单克隆抗体治疗且不太可能接受造血细胞移植的血液恶性肿瘤成人,评估4剂次灭活带状疱疹疫苗(ZVIN)的安全性和免疫原性。结果显示第4剂后约28天VZV特异性T细胞应答的几何倍数升高为4.34(90%CI:3.01,6.24),达到预设成功标准;85%(68/80)报告至少1例不良事件,未出现疫苗株VZV阳性皮疹。
要点
- 第4剂后28天VZV特异性T细胞应答几何倍数升高4.34(90%CI:3.01,6.24),达到预设成功标准。
- 85%(68/80)报告至少1例不良事件,44%(35/80)报告至少1例注射部位不良事件,74%(59/80)报告至少1例全身性不良事件。
- 未出现疫苗株VZV阳性的皮疹PCR结果,不良事件频率未随后续剂次增加。
核心结论
- 在接受抗CD20单克隆抗体治疗的血液恶性肿瘤成人中,ZVIN耐受良好,并在第4剂后约28天诱导出有统计学意义的VZV特异性T细胞应答。
研究设计与样本
- 开放标签、单臂、多中心I期研究(NCT01460719),纳入80例接受抗CD20单克隆抗体治疗且不太可能接受造血细胞移植的血液恶性肿瘤成人。
- 4剂次ZVIN方案,剂次间隔约30天,受试者年龄≥18岁。
- 第1剂前和第4剂后28天采集血样,用干扰素-γ酶联免疫斑点法(IFN-γ ELISPOT)检测VZV特异性T细胞应答。
主要发现
- 第4剂后28天IFN-γ ELISPOT检测的VZV特异性免疫应答几何倍数升高为4.34(90%CI:3.01,6.24),p值<0.001。
- 85%(68/80)报告至少1例不良事件,44%(35/80)报告至少1例注射部位不良事件,74%(59/80)报告至少1例全身性不良事件。
- 大多数全身性不良事件为非严重且研究者认为与接种无关,不良事件频率未随后续剂次增加。
- 未出现受种者皮疹PCR检测疫苗株VZV阳性的情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunocompromised patients can experience significant morbidity and occasional mortality from complications associated with herpes zoster (HZ), but live attenuated HZ vaccine is contraindicated for these patients. Inactivated zoster vaccine (ZVIN) is in development for prevention of HZ in immunocompromised patients. However, there are limited data in the literature regarding the effect of anti-CD20 monoclonal antibodies on vaccine-related cell-mediated immune response. This study evaluated safety and immunogenicity of ZVIN in patients with hematologic malignancies (HM) receiving anti-CD20 monoclonal antibodies (alone or in combination chemotherapy regimens) and not likely to undergo hematopoietic cell transplant (HCT) (n=80). METHODS: This was an open-label, single-arm, multicenter Phase I study (NCT01460719) of a 4-dose ZVIN regimen (∼30days between doses) in patients ⩾18years old. Blood samples were collected prior to dose 1 and 28days Postdose 4 to measure varicella zoster virus (VZV)-specific T-cell responses using interferon-γ enzyme-linked immunospot (IFN-γ ELISPOT). The primary hypothesis was that ZVIN would elicit significant VZV-specific immune responses at ∼28days Postdose 4, with a geometric fold rise (GMFR) >1.0. All vaccinated patients were evaluated for adverse events (AE) through 28days Postdose 4. RESULTS: ZVIN elicited a statistically significant VZV-specific immune response measured by IFN-γ ELISPOT at 28days Postdose 4 (GMFR=4.34 [90% CI:3.01, 6.24], p-value<0.001), meeting the pre-specified success criterion. Overall, 85% (68/80) of patients reported ⩾1 AE, 44% (35/80) reported ⩾1 injection-site AE, and 74% (59/80) reported ⩾1 systemic AE. The majority of systemic AEs were non-serious and considered unrelated to vaccination by the investigator. Frequencies of AEs did not increase with subsequent doses of vaccine. No recipient of ZVIN had rash polymerase chain reaction (PCR) positive for VZV vaccine strain. CONCLUSIONS: In adults with HM receiving anti-CD20 monoclonal antibodies, ZVIN was well-tolerated and elicited statistically significant VZV-specific T-cell responses ∼28days Postdose 4. CLINICALTRIALS.GOV identifier: NCT01460719.
引用
- Parrino J, McNeil SA, Lawrence SJ, et al. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies. Vaccine. 2017. PMID: 28268074. doi:10.1016/j.vaccine.2016.10.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。